secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2024-09-09T23:59:59+00:00
Accession:  0001326732-24-000046
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor unveils autoimmune pipeline, reports initial XmAb819 RECIST responses in ccRCC
--------------------------------------------------------------------------------

- XmAb942 (anti-TL1A) Phase 1 healthy volunteer study starts Q4 2024; interim data in H1 2025.
- Plamotamab (CD20xCD3) Phase 1b/2a in multi-drug resistant RA to begin H1 2025.
- XmAb657 (CD19xCD3) Phase 1 in autoimmune disease starts H2 2025; preclinical B-cell depletion >99.98%.
- XmAb819 (ENPP3xCD3) shows RECIST responses in ccRCC; dose escalation continues, target dose by YE 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673224000046/0001326732-24-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673224000046/xncr-20240909.htm
  HTML page:      https://secwatch.observer/filing/0001326732-24-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer